Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 May 16:11:132.
doi: 10.1186/1741-7015-11-132.

Personalized medicine in psychiatry: problems and promises

Affiliations
Review

Personalized medicine in psychiatry: problems and promises

Uzoezi Ozomaro et al. BMC Med. .

Abstract

The central theme of personalized medicine is the premise that an individual's unique physiologic characteristics play a significant role in both disease vulnerability and in response to specific therapies. The major goals of personalized medicine are therefore to predict an individual's susceptibility to developing an illness, achieve accurate diagnosis, and optimize the most efficient and favorable response to treatment. The goal of achieving personalized medicine in psychiatry is a laudable one, because its attainment should be associated with a marked reduction in morbidity and mortality. In this review, we summarize an illustrative selection of studies that are laying the foundation towards personalizing medicine in major depressive disorder, bipolar disorder, and schizophrenia. In addition, we present emerging applications that are likely to advance personalized medicine in psychiatry, with an emphasis on novel biomarkers and neuroimaging.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Personalized medicine. Forefront shows the schematic of the various factors that play into developing a unique phenotypic profile: genetic alterations, epigenetic modifications, clinical diagnostics, biomarker changes, and environmental changes. Upon obtaining a unique phenotypic profile, the psychiatrist is in a better position to either predict susceptibility to disease or make an accurate diagnosis. This, is in turn, allows for therapy targeted to the individual. Background: each individual will have differences in these components, giving rise to a unique phenotypic profile.
Figure 2
Figure 2
‘Modified’ central dogma. The central dogma of molecular biology states that DNA is transcribed to RNA, which is then translated into protein. In light of the emerging importance of non-coding RNAs, this diagram shows how non-coding RNAs serve to regulate each step in the central dogma, including regulating their own transcription.

Similar articles

  • [Building precision psychiatry: why and how?].
    Chaumette B, Yrondi A, Godin O, Krebs MO, Boyer L, Samalin L, Llorca PM, Leboyer M. Chaumette B, et al. Med Sci (Paris). 2025 May;41(5):416-424. doi: 10.1051/medsci/2025072. Epub 2025 May 26. Med Sci (Paris). 2025. PMID: 40418003 Review. French.
  • Moving toward precision and personalized treatment strategies in psychiatry.
    Comai S, Manchia M, Bosia M, Miola A, Poletti S, Benedetti F, Nasini S, Ferri R, Rujescu D, Leboyer M, Licinio J, Baune BT, Serretti A. Comai S, et al. Int J Neuropsychopharmacol. 2025 May 9;28(5):pyaf025. doi: 10.1093/ijnp/pyaf025. Int J Neuropsychopharmacol. 2025. PMID: 40255203 Free PMC article. Review.
  • Pharmacogenomic Biomarkers and Their Applications in Psychiatry.
    Kam H, Jeong H. Kam H, et al. Genes (Basel). 2020 Nov 30;11(12):1445. doi: 10.3390/genes11121445. Genes (Basel). 2020. PMID: 33266292 Free PMC article. Review.
  • [Brain imaging and the first success of precision psychiatry].
    Laidi C, Bouaziz N, Haffen E, Domenech P, Duchesnay E, Favre P, Fakra É, Houenou J, Iftimovici A, Lefrere A, Polosan M, Sescousse G, Sauvaget A, Jardri R. Laidi C, et al. Med Sci (Paris). 2025 May;41(5):500-507. doi: 10.1051/medsci/2025061. Epub 2025 May 26. Med Sci (Paris). 2025. PMID: 40418012 Review. French.
  • [Neurodevelopment: a transnosographic dimension].
    Iftimovici A, Jardri R, Lefebvre A, Mallet J, Lefrere A. Iftimovici A, et al. Med Sci (Paris). 2025 May;41(5):451-459. doi: 10.1051/medsci/2025071. Epub 2025 May 26. Med Sci (Paris). 2025. PMID: 40418007 Review. French.

Cited by

References

    1. Myers AJ, Nemeroff CB. New Vistas in the Management of Treatment-Refractory Psychiatric Disorders: Genomics and Personalized Medicine. Focus. 2010;8:525–535.
    1. Mehta R, Jain RK, Badve S. Personalized medicine: the road ahead. Clin Breast Cancer. 2011;11:20–26. - PubMed
    1. Conneally PM. Huntington disease: genetics and epidemiology. Am J Hum Genet. 1984;36:506–526. - PMC - PubMed
    1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19. - PubMed
    1. Risch SC, Nemeroff CB. Neurochemical alterations of serotonergic neuronal systems in depression. J Clin Psychiatry. 1992;53:3–7. - PubMed

Publication types